APO Research
Talk to an analyst

APO RESEARCH · REPORT

23-Valent Pneumococcal Polysaccharide Vaccine

23-Valent Pneumococcal Polysaccharide Vaccine is a vaccine product category defined by its pneumococcal antigen composition and formulation.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.

The commercial boundary

The selected edition describes a market scope. Product approvals, labelled use and clinical acceptance require their own evidence; neither report segmentation nor an illustrative image establishes medical suitability.

Which antigen composition and formulation define the vaccine?

Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.

Selected research

Industry Research

23-Valent Pneumococcal Polysaccharide Vaccine Industry Research Report 2026

2 January 2026113 pages

Choose your research edition.

Industry Research23-Valent Pneumococcal Polysaccharide Vaccine Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

The major players in global 23-Valent Pneumococcal Polysaccharide Vaccine market include MSD, Sanofipasteur, etc. The top 2 players occupy about 80% shares of the global market. North America and Europe are main markets, they occupy about 50% of the global market. Single Dose Vial is the main type, with a share about 60%. For Children (2-10) is the main application, which holds a share about 40%.

Read the full market overview

Report Scope

This report quantifies the global 23-Valent Pneumococcal Polysaccharide Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Dose), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Dose) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

23-Valent Pneumococcal Polysaccharide Vaccine Market by Company

MSD

Sanofipasteur

CDIBP

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Type

Single Dose Vial

Pre-filled Syringe

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Application

For Children (2-10)

For Person (10-64)

For The Old (Above or equal to 65)

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 23-Valent Pneumococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of 23-Valent Pneumococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 23-Valent Pneumococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of 23-Valent Pneumococcal Polysaccharide Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of 23-Valent Pneumococcal Polysaccharide Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose) of Manufacturers (2021-2026) Table 7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market 23-Valent Pneumococcal Polysaccharide Vaccine Average Price (US$/Dose) of Manufacturers (2021-2026) Table 11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Product Type & Application Table 14. Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global 23-Valent Pneumococcal Polysaccharide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. MSD Company Information Table 19. MSD Business Overview Table 20. MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 21. MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 22. MSD Recent Developments Table 23. Sanofipasteur Company Information Table 24. Sanofipasteur Business Overview Table 25. Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 26. Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 27. Sanofipasteur Recent Developments Table 28. CDIBP Company Information Table 29. CDIBP Business Overview Table 30. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 31. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 32. CDIBP Recent Developments Table 33. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 34. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (K Dose) Table 35. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 36. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2027-2032) & (K Dose) Table 37. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 38. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 39. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2026) Table 40. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 41. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2027-2032) Table 42. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 44. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 45. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 46. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 47. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 49. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 50. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 51. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 52. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 54. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 55. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 56. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 57. South America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. South America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 59. South America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 60. South America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 61. South America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 62. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 64. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 65. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 66. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 67. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (K Dose) Table 68. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (K Dose) Table 69. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2026) Table 70. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2027-2032) Table 71. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 72. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 73. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2026) Table 74. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2027-2032) Table 75. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2021-2026) & (US$/Dose) Table 76. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2027-2032) & (US$/Dose) Table 77. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (K Dose) Table 78. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (K Dose) Table 79. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2026) Table 80. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2027-2032) Table 81. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 82. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 83. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2026) Table 84. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2027-2032) Table 85. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2021-2026) & (US$/Dose) Table 86. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2027-2032) & (US$/Dose) Table 87. Key Raw Materials Table 88. Raw Materials Key Suppliers Table 89. 23-Valent Pneumococcal Polysaccharide Vaccine Distributors List Table 90. 23-Valent Pneumococcal Polysaccharide Vaccine Customers List Table 91. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends Table 92. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers Table 93. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints Table 94. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. 23-Valent Pneumococcal Polysaccharide Vaccine Product Image Figure 5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (2021-2032) & (K Dose) Figure 8. Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Price (US$/Dose) & (2021-2032) Figure 9. Single Dose Vial Product Image Figure 10. Pre-filled Syringe Product Image Figure 11. For Children (2-10) Product Image Figure 12. For Person (10-64) Product Image Figure 13. For The Old (Above or equal to 65) Product Image Figure 14. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 23-Valent Pneumococcal Polysaccharide Vaccine Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region in 2025 Figure 20. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region in 2025 Figure 21. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 22. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 23. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 24. United States 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 28. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 29. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 30. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 41. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 43. China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 52. South America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 53. South America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 54. Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country in 2025 Figure 58. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Country (2021-2032) Figure 60. Egypt 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032) Figure 66. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032) Figure 67. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price (US$/Dose) by Type (2021-2032) Figure 68. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032) Figure 69. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032) Figure 70. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price (US$/Dose) by Application (2021-2032) Figure 71. 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain Figure 72. 23-Valent Pneumococcal Polysaccharide Vaccine Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Single Dose Vial
  • Pre-filled Syringe
Applications
  • For Children (2-10)
  • For Person (10-64)
  • For The Old (Above or equal to 65)
Companies covered
  • MSD
  • Sanofipasteur
  • CDIBP

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size (2021-2032)
  4. 2.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (2021-2032)
  5. 2.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Average Price (2021-2032)
  6. 2.3 23-Valent Pneumococcal Polysaccharide Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Single Dose Vial
  9. 2.3.3 Pre-filled Syringe
  10. 2.4 23-Valent Pneumococcal Polysaccharide Vaccine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 For Children (2-10)
  13. 2.4.3 For Person (10-64)
  14. 2.4.4 For The Old (Above or equal to 65)
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose) of Manufacturers (2021-2026)
  3. 3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global 23-Valent Pneumococcal Polysaccharide Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Established Date
  9. 3.9 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 MSD
  2. 4.1.1 MSD Company Information
  3. 4.1.2 MSD Business Overview
  4. 4.1.3 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  6. 4.1.5 MSD Recent Developments
  7. 4.2 Sanofipasteur
  8. 4.2.1 Sanofipasteur Company Information
  9. 4.2.2 Sanofipasteur Business Overview
  10. 4.2.3 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  12. 4.2.5 Sanofipasteur Recent Developments
  13. 4.3 CDIBP
  14. 4.3.1 CDIBP Company Information
  15. 4.3.2 CDIBP Business Overview
  16. 4.3.3 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  18. 4.3.5 CDIBP Recent Developments
5 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Scenario by Region
  1. 5.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2027-2032
  5. 5.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
  16. 5.5.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  18. 5.5.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
  41. 5.7.1 South America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  43. 5.7.3 South America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032) & (K Dose)
  3. 6.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032) & (K Dose)
  3. 7.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain Analysis
  2. 8.1.1 23-Valent Pneumococcal Polysaccharide Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 23-Valent Pneumococcal Polysaccharide Vaccine Production Mode & Process
  5. 8.2 23-Valent Pneumococcal Polysaccharide Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 23-Valent Pneumococcal Polysaccharide Vaccine Distributors
  8. 8.2.3 23-Valent Pneumococcal Polysaccharide Vaccine Customers
9 Global 23-Valent Pneumococcal Polysaccharide Vaccine Analyzing Market Dynamics
  1. 9.1 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends
  2. 9.2 23-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers
  3. 9.3 23-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 9.4 23-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst